Melanoma

April 15, 2022

From the Co-Chairs, April 2022

Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
April 15, 2022

News in Brief, April 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 16, 2021

From the Co-Chairs, November 2021

Practice-changing trial results in melanoma; Group and committee leadership updates; remembering a dear colleague and friend
November 16, 2021

Trial Results: ASCO Highlights Practice-Changing Results in Melanoma

The phase III DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
November 16, 2021

Trial Spotlight: Ravi Amaravadi on the EA6191/BAMM2 Trial for Melanoma

This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma
March 31, 2021

Now Enrolling: EA6194 for Operable Melanoma

This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
May 29, 2020

From the Co-Chairs, May 2020

What we know about COVID-19; remembering Valerie Guild; spotlight on Indiana University's Melvin and Bren Simon Comprehensive Cancer Center
May 29, 2020

Remembering Valerie Guild, a Tireless Advocate for Patients with Melanoma

April 15, 2020

Now Enrolling: EA6183 Evaluating Encorafenib and Binimetinib in Metastatic Melanoma

A single-arm phase II trial evaluating the effectiveness of treatment before surgery with encorafenib and binimetinib
April 15, 2020

Remembering Uma Rao, MD